Understanding APLA Diagnosis in Antiphospholipid Syndrome

Introduction

Antiphospholipid antibodies (APLAs) are pivotal autoantibodies in the context of antiphospholipid syndrome (APS), a systemic autoimmune disorder. APS is clinically defined by the persistent presence of these APLAs alongside thrombotic events, pregnancy morbidity, or both. These antibodies, targeting phospholipid-binding proteins, paradoxically promote in vivo thrombosis despite prolonging in vitro coagulation tests. Venous thrombosis commonly affects the lower limbs, while arterial thrombosis often involves the cerebral circulation; however, thrombosis can manifest in any organ. Catastrophic antiphospholipid syndrome (CAPS) represents a critical, high-mortality complication. Effective management strategies are contingent upon the clinical presentation and Apla Diagnosis. This article delves into the diagnostic criteria for APS, emphasizing the crucial role of APLA diagnosis and the importance of interprofessional care for patients with this complex condition.

Etiology of Antiphospholipid Syndrome and the Role of APLAs

Antiphospholipid syndrome can arise as a primary condition without association with other autoimmune diseases or secondary to autoimmune conditions, most notably systemic lupus erythematosus (SLE), which accounts for approximately 40% of APS cases. Studies reveal the presence of APLAs in various patient populations, including pregnant women (6%), stroke patients (13.5%), and individuals with deep vein thrombosis (DVT) (9.5%), underscoring the broad clinical relevance of APLA diagnosis.

Genetic predispositions, such as mutations in coagulation factors and specific HLA alleles (HLA-DR7, DR4, DRw53, DQw7, and C4 null alleles), have been linked to an increased risk of APLA-associated thrombosis. Infections, particularly viral infections like Borrelia burgdorferi, Coxiella burnetii, Treponema pallidum, hepatitis C, HIV, COVID-19, Epstein-Barr virus (EBV), and Leptospira, are associated with elevated APLA levels compared to bacterial infections. Notably, a meta-analysis indicated that nearly 50% of COVID-19 patients tested positive for APLAs, with lupus anticoagulant being the most common type, although no increased thrombotic risk was observed in APLA-positive COVID-19 patients in this analysis.

Certain medications, including chlorpromazine, procainamide, quinidine, and phenytoin, can also induce APLA production. Low levels of APLAs can be transient and clinically insignificant, necessitating repeat positive antibody tests at least 12 weeks apart for a definitive APLA diagnosis in APS.

APS classification further distinguishes between obstetric, thrombotic, or combined presentations, as well as the presence of life-threatening multiorgan involvement. Obstetric APS is defined by pregnancy complications such as premature birth due to preeclampsia, fetal death after 10 weeks of gestation, placental insufficiency, or recurrent embryonic losses before 10 weeks, in conjunction with persistent laboratory evidence of APLAs. Patients exhibiting both thromboembolic events and obstetric complications are categorized as having both thrombotic and obstetric APS.

Epidemiology and Prevalence of APLAs

The incidence of APS in the United States is estimated at 2.1 per 100,000 individuals, with a prevalence of 50 per 100,000. European rates are slightly lower, with an incidence of 1.1 per 100,000. Asian populations are believed to have even lower rates, with South Korea reporting an incidence of 0.75 per 100,000 and a prevalence of 6.19 per 100,000. These epidemiological figures highlight the geographical variability in APS and APLA prevalence.

Low-titer anticardiolipin antibodies can be found in up to 10% of healthy individuals, and the likelihood of a positive APLA test increases with age. A study of centenarians without known autoimmune disease revealed that 54% were positive for anti-β2GPI-IgG and 21% for anticardiolipin-IgG, while none tested positive for lupus anticoagulant, suggesting lupus anticoagulant may be a more specific marker for clinically significant APLAs. However, high titers and persistent positivity of APLAs are rare in healthy individuals, occurring in less than 1%. Patients with SLE face a significantly elevated risk of both positive APLA tests and APLA-related clinical outcomes, with 50% to 70% of SLE patients with positive APLAs progressing to APS.

APLA positivity is also observed in up to 20% of rheumatoid arthritis patients. In couples with recurrent abortions, APLA positivity was found in 20% of cases. Furthermore, 14% of patients with recurrent venous thromboembolism tested positive for APLAs, such as lupus anticoagulant or anticardiolipin antibodies, demonstrating the association between APLA diagnosis and recurrent thrombotic events.

Pathophysiology: How APLAs Lead to Thrombosis

While not all individuals with APLAs develop APS, a strong correlation exists between APLA presence and the risk of venous thrombosis, myocardial infarction, and ischemic stroke. The specific APLA profile, including antibody type, titer, and underlying comorbidities, influences the likelihood of developing clinical APS. Triple positivity for lupus anticoagulant and high titers of anticardiolipin and anti-β2GPI antibodies indicates a high risk, whereas isolated or intermittent positivity or low titers of anticardiolipin or anti-β2GPI antibodies suggest a lower risk. Patients with SLE, cardiovascular risk factors, recurrent thrombosis despite anticoagulation, or a history of arterial thrombosis are also at increased risk of recurrent thrombosis. APLAs are not merely serological markers but are considered pathogenic in APS, playing a direct role in thrombosis (See Figure 1).

Figure 1: Antiphospholipid Syndrome. This image illustrates the connection between antiphospholipid antibodies (APLAs) and antiphospholipid syndrome (APS), a condition marked by abnormal blood clotting. Grygiel-Górniak B, Mazurkiewicz Ł. Positive antiphospholipid antibodies: observation or treatment? J Thromb Thrombolysis. 2023 Aug;56(2):301-314.

The “two-hit” thrombosis model explains thrombus formation in APS. The first hit involves endothelial injury, while the second hit amplifies thrombus formation. Beta-2-glycoprotein-I, a key target of APLAs, does not bind to unstimulated endothelium under normal physiological conditions. One theory posits that in cases of unexplained endothelial injury, a redox imbalance within vascular beds may prime the endothelium. APS patients often have reduced levels of reduced, protective beta-2 glycoprotein-I. Annexin A2, an endothelial cell surface receptor, is upregulated under oxidative stress. Factors like smoking can induce endothelial injury and increase pro-thrombotic tendencies in individuals with lupus anticoagulants.

Plasma nitrite levels are lower in APS patients compared to healthy individuals. Reduced expression and activity of endothelial nitric oxide synthase lead to peroxynitrite and superoxide generation. Preclinical models demonstrate that domain I of beta-2 glycoprotein-I autoantibodies can antagonize endothelial nitric oxide synthase activity, resulting in monocyte adhesion and impaired nitric oxide-dependent arterial relaxation.

APLAs enhance tissue factor expression via intracellular signaling pathways following binding of anti-β2GPI autoantibodies to monocytes and endothelial cell multiprotein complexes. Autoantibodies in APS disrupt neutrophil and monocyte mitochondrial function and increase reactive oxygen species production, consequently promoting tissue factor expression. Complement activation and fibrinolysis inhibition by APLAs are also established mechanisms in APS pathogenesis.

In APS-related pregnancy loss, intraplacental thrombosis, complement pathway activation, disruption of trophoblast growth and differentiation, impaired trophoblastic invasion, and hormonal effects are implicated. A study of nearly 600 pregnant women with fetal loss after 20 weeks showed that 9.6% were positive for at least one APLA, highlighting the importance of APLA diagnosis in recurrent pregnancy loss.

Histopathological Findings in APS

Renal biopsies in APS patients with kidney involvement reveal thrombotic microangiopathy, characterized by fibrin thrombi in glomeruli or arterioles without significant inflammation or immune complexes, fibrous intimal hyperplasia, and focal cortical atrophy. Thyroidization may also be present, and these lesions need to be differentiated from lupus nephritis lesions.

Skin biopsies from non-healing ulcers are typically non-specific but may show small vessel and endothelial proliferation without significant vasculitis. Cardiac biopsies, if performed, might show small vessel thrombosis. Bronchoalveolar lavage may reveal hemosiderin-laden macrophages, and lung biopsies could show capillaritis or microthrombi, reflecting the diverse histopathological manifestations of APS across different organs.

Clinical Presentation: History and Physical Examination in APLA Positive Patients

The clinical spectrum of APS ranges from asymptomatic APLA positivity to severe CAPS. Vascular thrombosis (arterial or venous) and pregnancy-related complications are the defining clinical features. However, non-criteria manifestations involving various organ systems are also recognized.

Vascular Thrombosis in APS

APS can cause arterial or venous thrombosis in any organ system. Thrombotic events can be isolated or recurrent and may occur in unusual locations such as upper extremity thrombosis, Budd-Chiari syndrome, and sagittal sinus thrombosis. DVTs are the most common venous manifestation and can lead to pulmonary embolism and pulmonary hypertension. Other venous thrombosis sites include pelvic, renal, mesenteric, hepatic, portal, axillary, ocular, sagittal, and inferior vena cava.

Arterial thrombosis can affect arteries of any size, from the aorta to capillaries. Transient ischemic attacks (TIAs) and ischemic stroke are the most frequent arterial manifestations. The occurrence of TIAs or stroke in young individuals without typical atherosclerosis risk factors should raise suspicion for APS. Other arterial thrombosis sites include retinal, brachial, coronary, mesenteric, and peripheral arteries. Arterial thrombosis in APS carries a poor prognosis due to a high recurrence risk.

Pregnancy Morbidity Associated with APLAs

Pregnancy loss is a significant concern in APS, particularly in the second or third trimester. While genetic and chromosomal abnormalities are the most common causes of early pregnancy loss, fetal loss after 20 weeks gestation is associated with approximately 10% APLA positivity. Triple positivity for lupus anticoagulant, anticardiolipin, and anti-β2GPI antibodies, prior pregnancy loss, thrombosis history, and SLE are risk factors for adverse pregnancy outcomes in APS. Besides pregnancy losses, other pregnancy complications in APS include preeclampsia, fetal distress, premature birth, intrauterine growth retardation, placental insufficiency, placental abruption, and HELLP syndrome.

Cutaneous, Valvular, Hematological, Neurological, Cardiac, Pulmonary, and Renal Involvement

Cutaneous manifestations in APS are non-specific, with livedo reticularis being the most common. However, it can occur in healthy individuals and other conditions like SLE, vasculitis, and Sneddon syndrome. Skin ulcerations, nail-fold infarcts, digital gangrene, superficial thrombophlebitis, and necrotizing purpura are also reported.

Cardiac valve involvement is frequent in APS, with studies reporting prevalence as high as 80%. Mitral and aortic valves are most commonly affected, showing thickening, nodules, and vegetations on echocardiography, potentially leading to regurgitation or stenosis.

Thrombocytopenia is seen in over 15% of APS cases, though severe thrombocytopenia with hemorrhage is rare. A positive Coombs test is common, but hemolytic anemia is infrequent.

Neurological complications include TIAs and ischemic stroke, potentially recurrent, leading to cognitive dysfunction, seizures, and multi-infarct dementia. Blindness from retinal artery or vein occlusion and sudden sensorineural hearing loss have also been reported.

Cardiac involvement can manifest as myocardial infarction and cardiac emboli. Non-ST segment elevation myocardial infarction with normal coronary angiography and abnormal cardiac MRI findings may suggest APS.

Pulmonary involvement includes pulmonary thromboembolism from DVT, leading to pulmonary hypertension, and diffuse pulmonary hemorrhage from pulmonary capillaritis.

Renal manifestations include hypertension, proteinuria, and renal failure due to thrombotic microangiopathy, although non-specific. Renal artery thrombosis leading to refractory hypertension and focal cortical atrophy are also reported.

Catastrophic Antiphospholipid Syndrome (CAPS)

CAPS is a rare, life-threatening APS complication, affecting less than 1% of APS patients, with a high mortality rate (48%), especially in SLE patients or those with cardiac, pulmonary, renal, and splenic involvement. CAPS is characterized by rapid thrombosis in multiple organs, typically over days, affecting small and medium-sized arteries. Clinical presentations vary widely depending on the organs involved and may include peripheral thrombosis, pulmonary complications, renal manifestations, cutaneous symptoms, cerebral manifestations, cardiac complications, hematological issues, and gastrointestinal involvement.

Common triggers for CAPS include stopping anticoagulation in APS patients, infections, and surgical procedures. Prompt infection management and perioperative anticoagulation are crucial.

Preliminary CAPS classification criteria from 2003 include:

• Involvement of 3 or more organs, systems, or tissues.
• Manifestations developing simultaneously or within < 1 week.
• Histopathological confirmation of small vessel occlusion in at least one organ/tissue.
• Laboratory confirmation of APLA presence.

Definite CAPS requires all four criteria, while probable CAPS requires three criteria with incomplete fulfillment of the fourth.

Evaluation and APLA Diagnosis in APS

APLA diagnosis is central to APS diagnosis, requiring laboratory confirmation of lupus anticoagulant or moderate-to-high titers of IgG or IgM anticardiolipin or anti-β2GPI antibodies, in addition to clinical criteria. Repeat positive APLA testing is required 12 weeks after the initial positive test to exclude transient antibodies. Diagnosis is questionable if the interval is less than 12 weeks or if the gap between clinical manifestations and positive tests is > 5 years.

Lupus Anticoagulant Test

A positive lupus anticoagulant test is a strong predictor of adverse pregnancy outcomes and is more specific but less sensitive than anticardiolipin antibodies for thrombosis prediction. A positive lupus anticoagulant test is found in 20% of patients with anticardiolipin antibodies, while anticardiolipin antibodies are found in 80% of those with a positive lupus anticoagulant test (See Figure 2).

Figure 2: Effect of Lupus Anticoagulant and Anticoagulants on Laboratory Testing. This table details how lupus anticoagulant and anticoagulation medications like warfarin and DOACs affect clotting and anticoagulation tests. Table: Effect of Lupus Anticoagulant and Anticoagulants on Laboratory Testing.

A false-positive syphilis test does not meet APS diagnostic criteria, but APLA assessment is advised in patients with prior thrombotic or adverse pregnancy events. Lupus anticoagulant indicates an in vitro inhibitor of phospholipid-dependent coagulation reactions, not directly related to bleeding risks. False-positive and false-negative results can occur in patients on heparin or warfarin.

The lupus anticoagulant test involves four steps:

1. Initial screening (e.g., aPTT, dilute Russell viper venom time) showing prolonged phospholipid-dependent clot formation.
2. Prolonged screening test persists after mixing patient plasma with normal platelet-poor plasma.
3. Correction or improvement of prolonged screening test with excess phospholipid, indicating phospholipid dependency.
4. Exclusion of other inhibitors.

Anticardiolipin and Anti-Beta-2-Glycoprotein-I Antibodies Assays

Anticardiolipin and anti-β2GPI antibodies are measured by ELISA, commonly testing for IgG and IgM isotypes. IgG antibodies correlate better with clinical manifestations than IgM or IgA. Titers > 40 IgG units are associated with thrombotic events, while lower titers have less proven association.

Other Laboratory Findings

Thrombocytopenia or anemia can be present in APS. Renal failure and proteinuria may indicate renal thrombotic microangiopathy. Erythrocyte sedimentation rate might be elevated during acute thrombosis, but inflammation markers are typically normal otherwise. SLE patients may have SLE-specific serologies (antinuclear, anti-dsDNA, anti-Smith antibodies). Hypocomplementemia is not typical in APS and suggests lupus nephritis if renal involvement is present.

Positive antinuclear and anti-dsDNA antibodies can occur in primary APS without SLE, and their presence alone does not diagnose SLE without clinical lupus features. Patients with multiple thrombotic events or pregnancy losses should be tested for other hypercoagulable states (hyperhomocysteinemia, factor V Leiden, prothrombin mutations, protein C, protein S, or antithrombin III deficiencies).

Classification Criteria for APS: Sapporo and ACR/EULAR

The initial Sapporo criteria (1999, updated 2006) require at least one clinical and one laboratory criterion for APS diagnosis.

Clinical Criteria (Sapporo):

• Vascular Thrombosis: One or more arterial, venous, or small-vessel thrombosis events in any organ, objectively confirmed by imaging or histopathology (excluding superficial venous thrombosis).
• Pregnancy Morbidity:
  • One or more unexplained fetal deaths of normal fetuses ≥ 10 weeks gestation.
  • One or more premature births of normal neonates < 34 weeks gestation due to preeclampsia, eclampsia, or placental insufficiency.
  • Three or more consecutive spontaneous abortions < 10 weeks gestation (excluding anatomical, hormonal, or parental chromosomal abnormalities).

Laboratory Criteria (Sapporo):

• Lupus anticoagulant detection in plasma on ≥ 2 occasions, ≥ 12 weeks apart.
• IgG or IgM anticardiolipin antibodies in serum/plasma at moderate-to-high titers (> 40 GPL or GPM, or > 99th percentile) by ELISA on ≥ 2 occasions, ≥ 12 weeks apart.
• IgG or IgM anti-β2GPI antibodies in serum/plasma at moderate-to-high titers (> 99th percentile) by ELISA on ≥ 2 occasions, ≥ 12 weeks apart.

The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive APLA test within 3 years of an APS-associated clinical criterion. Weighted criteria are then applied across 6 clinical (macrovascular venous/arterial thromboembolism, microvascular, obstetric, cardiac valve, hematologic) and 2 laboratory (lupus anticoagulant, IgG/IgM anticardiolipin or anti-β2GP1) domains. Patients scoring ≥ 3 points in both clinical and laboratory domains are classified as having APS. The new criteria show higher specificity (99% vs. 86%) but lower sensitivity (84% vs. 99%) compared to the 2006 Sapporo criteria. Detailed criteria are available at DOI: 10.1002/art.42624.

Treatment and Management Strategies for APS

Thrombosis Management: Primary and Secondary Prevention

EULAR guidelines provide specific recommendations for various clinical scenarios in APS management. Primary thromboprophylaxis in APLA-positive patients without prior thrombotic or pregnancy events is debated. Confirmatory APLA testing ≥ 12 weeks after initial testing is crucial. SLE patients with positive APLAs are at higher thrombosis risk, and hydroxychloroquine is recommended for its thromboprotective effects. Low-dose aspirin may also be considered. Prophylaxis with low-dose aspirin may be considered for other APLA-positive patients with high-risk APLA profiles (e.g., triple positivity) and thrombotic risk factors but no prior thrombosis.

Primary Prevention: High-risk patients include those with lupus anticoagulant, 2 or 3 positive APLAs, or persistently high APLA titers.

• High-risk APLA profile, no thrombosis history: low-dose aspirin (75-100 mg).
• SLE patients, no thrombosis/pregnancy complications:
  • High-risk APLA: prophylactic low-dose aspirin recommended.
  • Low-risk APLA: prophylactic low-dose aspirin may be considered.
  • Non-pregnant women, obstetric APS only: prophylactic low-dose aspirin after risk/benefit assessment.

Secondary Prevention:

• Arterial Thrombosis: Warfarin is generally preferred over DOACs. INR target of 2.0-3.0 is common, some suggest > 3.0.

  • LMWH for warfarin intolerance or non-response.
  • Recurrent thrombosis on warfarin: add aspirin, switch to LMWH, or increase INR target to > 3.0. Assess warfarin adherence and INR frequency.
  • DOACs may be considered if INR target unattainable on warfarin or contraindications exist. Dabigatran may be more effective than other DOACs due to its anti-factor IIa mechanism.
  • Elderly stroke patients with low-titer anticardiolipin antibodies can be treated with low-dose aspirin as low titers may be incidental.

• Lupus anticoagulant can falsely prolong aPTT, PT, and INR. Prothrombin levels or factor X activity measurement can mitigate this.

Triple Positivity: DOACs have shown inferiority to warfarin in trials for triple-positive APS, with increased thrombotic events in DOAC groups, leading to early study termination. Therefore, warfarin is recommended over DOACs for triple-positive APS (positive lupus anticoagulant, anticardiolipin, and anti-β2GP1) or arterial thrombosis with APS. Some guidelines recommend warfarin over DOACs for any thrombotic event (venous or arterial) in APS.

Pregnancy Management in APS

Pregnant women with positive APLAs require close monitoring for fetal well-being and maternal complications. Treatment aims to reduce adverse fetal outcomes and depends on the clinical scenario. Warfarin is teratogenic and avoided in pregnancy. DOACs lack safety data and are also avoided. LMWH or unfractionated heparin can be used, with LMWH preferred for better bioavailability, longer half-life, once-daily dosing, and lower risks of thrombocytopenia and osteoporosis.

EULAR recommendations for pregnant women:

• Positive APLA, no arterial/venous thrombosis history:
  • First pregnancy: no treatment.
  • Single pregnancy loss < 10 weeks gestation: no treatment.
  • High-risk APLA, no thrombosis/pregnancy complications: consider low-dose aspirin.
• Delivery < 34 weeks gestation due to preeclampsia, eclampsia, or placental insufficiency: low-dose aspirin or low-dose aspirin plus prophylactic heparin based on risk profile.
• Less defined criteria (2 miscarriages < 10 weeks or delivery > 34 weeks due to preeclampsia/eclampsia): low-dose aspirin or prophylactic heparin based on risk profile.
• Definite obstetric APS with recurrent pregnancy complications despite low-dose aspirin and prophylactic heparin/LMWH: consider increasing heparin to therapeutic dose or adding hydroxychloroquine or low-dose prednisolone in the first trimester. IVIG may be considered in highly selected cases when other treatments fail.
• Thrombotic APS history: combination of low-dose aspirin and therapeutic heparin during pregnancy. Switch from warfarin to therapeutic heparin/LMWH upon pregnancy confirmation, ideally before week 6, due to warfarin’s teratogenicity.

Management of Non-Criteria Manifestations and CAPS

Anticoagulation role in non-criteria APS manifestations is unclear. Thrombocytopenia (> 50,000/mL3 platelets) usually requires no treatment; corticosteroids ± IVIG or rituximab for platelet counts < 50,000/mL3. Splenectomy can be beneficial in refractory thrombocytopenia.

Renal thrombotic microangiopathy requires renal biopsy to rule out lupus nephritis, especially in SLE patients. Anticoagulation and corticosteroids can be used for thrombotic microangiopathy. Effective treatment for cardiac valve nodules/deformities is unknown; anticoagulation is recommended for embolism or intracardiac thrombus evidence.

Catastrophic Antiphospholipid Syndrome (CAPS): Early CAPS diagnosis is critical due to high mortality. Combination therapy with glucocorticoids, heparin, and plasma exchange or IVIG is recommended as first-line treatment over single agents. Treat precipitating factors (infections, gangrene, malignancy). Refractory CAPS may require B-cell depletion (rituximab, cyclophosphamide) or complement inhibition (eculizumab) based on case reports.

Follow-up and Monitoring

Stable anticoagulated APS patients without systemic autoimmune disease can have outpatient visits once or twice yearly. Coagulation studies are done pre-anticoagulation and during therapy for dosing. Biochemistry panel (renal function tests) and CBC are used for monitoring. Repeat APLA testing is usually not indicated unless for future treatment decisions. Symptomatic organ involvement requires appropriate evaluations.

Differential Diagnosis of APS

APS-related thrombosis must be differentiated from other thrombophilic conditions like hyperhomocysteinemia, factor V Leiden, prothrombin mutations, or protein C, protein S, or antithrombin III deficiencies.

APS nephropathy must be differentiated from thrombotic thrombocytopenic purpura (TTP), vasculitis, hemolytic uremic syndrome, malignant hypertension, and lupus nephritis, often requiring kidney biopsy for definitive diagnosis.

Prognosis in APS

European studies report 90%-94% 10-year survival in APS, but morbidity is high, with > 30% developing permanent organ damage and > 20% severe disability at 10-year follow-up. Poor prognostic factors include CAPS, pulmonary hypertension, nephropathy, CNS involvement, and extremity gangrene.

Primary and secondary APS prognoses are similar, but secondary APS may have increased morbidity due to underlying rheumatic/autoimmune disorders. Lupus patients with APLAs have a higher risk of neuropsychiatric disorders. APLA elevation in malignancy is associated with poor prognosis, with or without thrombosis.

Complications of Antiphospholipid Syndrome

APS complications include fetal loss, stroke, pulmonary embolism, pulmonary hypertension, valvular abnormalities, acute coronary syndrome, mesenteric thrombosis, and hepatic veno-occlusive disease. Perioperative complications are common in APS due to surgery-related prothrombotic risks. Perioperative anticoagulation strategies require careful planning in APS patients.

Consultations in APS Management

APS management often involves internists, rheumatologists, hematologists, and obstetricians.

Deterrence and Patient Education

Patient education on APS complications and symptoms requiring medical attention (e.g., TIA symptoms) is essential. Clear communication of medication regimens and adherence importance is crucial. Warfarin patients need INR monitoring and dietary guidance to avoid drug-food interactions.

Pearls and Key Considerations in APS

Identifying and managing other prothrombotic risk factors (hyperlipidemia, smoking, hypertension, oral contraceptives) is vital in APS patients.

Enhancing Healthcare Team Outcomes in APS

Optimal APS management requires an interprofessional team approach. Primary care physicians are crucial for initial identification. Hematologists and rheumatologists are key for diagnosis, management, and follow-up. Neurologists, nephrologists, cardiologists, and dermatologists may be needed for organ-specific involvement. Anticoagulation clinics are important for warfarin monitoring. In pregnancy, obstetrics and maternal-fetal medicine specialists are essential. Pharmacists help manage drug interactions and warfarin dosing, while specialty-trained nurses can also monitor warfarin therapy. Effective communication and close patient monitoring within the interprofessional team are crucial for successful APS management.

Review Questions

(Review questions from the original article would be included here if needed for the new article format)

References

(References from the original article are listed here as provided)

1.Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023 Feb 27;380:e069717. [PubMed: 36849186]
2.Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018 Sep 27;379(13):1290. [PubMed: 30257161]
3.Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002 Mar 07;346(10):752-63. [PubMed: 11882732]
4.Grygiel-Górniak B, Mazurkiewicz Ł. Positive antiphospholipid antibodies: observation or treatment? J Thromb Thrombolysis. 2023 Aug;56(2):301-314. [PMC free article: PMC10234248] [PubMed: 37264223]
5.Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002 Apr;87(4):599-605. [PubMed: 12008941]
6.Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022 Jan 05;23(12):85. [PMC free article: PMC8727975] [PubMed: 34985614]
7.Garra W, Carmi O, Kivity S, Levy Y. Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review. Medicine (Baltimore). 2023 Feb 10;102(6):e32949. [PMC free article: PMC9907943] [PubMed: 36820549]
8.Lim W. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2013;2013:675-80. [PubMed: 24319251]
9.Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006 Apr;8(2):100-8. [PubMed: 16569368]
10.Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril. 1996 Jul;66(1):24-9. [PubMed: 8752606]
11.Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995 Nov 15;86(10):3685-91. [PubMed: 7579334]
12.Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992 Dec 15;117(12):997-1002. [PubMed: 1443986]
13.Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 Jun;93(6):1147-52. [PubMed: 15968401]
14.Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost. 2012 Jun;38(4):339-47. [PubMed: 22467528]
15.Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D., ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. [PubMed: 37635643]
16.Bouabdella S, Dikhaye S, Zizi N. [Extremity necrosis revealing antiphospholipid syndrome]. Rev Prat. 2023 Jan;73(1):64. [PubMed: 36820458]
17.Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Cárdenas A, Keirns C, Amigo MC. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J. 1999 May;137(5):973-8. [PubMed: 10220649]
18.Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa MC, Hughes GR, Ingelmo M., Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. [PubMed: 11953980]
19.Yao WC, Leong KH, Chiu LT, Chou PY, Wu LC, Chou CY, Kuo CF, Tsai SY. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022 Sep 01;20(1):50. [PMC free article: PMC9434885] [PubMed: 36050731]
20.Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, Ramos-Casals M, Ingelmo M, Piette JC, Shoenfeld Y, Asherson RA., Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005 Aug;64(8):1205-9. [PMC free article: PMC1755612] [PubMed: 15708888]
21.Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct;78(10):1296-1304. [PMC free article: PMC11034817] [PubMed: 31092409]
22.Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y., Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530-4. [PubMed: 12892393]
23.Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. [PubMed: 16420554]
24.Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000 Jul 10;160(13):2042-8. [PubMed: 10888978]
25.Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. [PubMed: 30002145]
26.Capecchi M, Abbattista M, Ciavarella A, Uhr M, Novembrino C, Martinelli I. Anticoagulant Therapy in Patients with Antiphospholipid Syndrome. J Clin Med. 2022 Nov 26;11(23) [PMC free article: PMC9741036] [PubMed: 36498557]
27.Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood. 2007 Nov 01;110(9):3122-7. [PubMed: 17644740]
28.Yelnik CM, Lambert M, Drumez E, Le Guern V, Bacri JL, Guerra MM, Laskin CA, Branch DW, Sammaritano LR, Morel N, Guettrot-Imbert G, Launay D, Hachulla E, Hatron PY, Salmon JE, Costedoat-Chalumeau N. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus. 2018 Sep;27(10):1679-1686. [PubMed: 30016929]
29.Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol. 2000 Dec;27(12):2817-21. [PubMed: 11128669]

(Disclosure statements from the original article are listed here as provided)

Disclosure: Jean Bustamante declares no relevant financial relationships with ineligible companies.

Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Rout declares no relevant financial relationships with ineligible companies.

Disclosure: Mayank Singhal declares no relevant financial relationships with ineligible companies.